Introduction: We examined the cost-eff ectiveness of the three diff erent D-dimer measurements in the screening of DVT in models with and without calculation of pre-test probability (PTP) score. Moreover, we calculated the minimal cost in DVT detection. . According to sensitivity analysis, the Hemosil D-dimer HS assay was the most cost eff ective alternative when one patient was admitted to the vascular ambulance per day. Vidas D-dimer Exclusion II assay was the most cost eff ective alternative when more than one patient were admitted to the vascular ambulance per day. Cost minimisation analysis indicated that selection of patients according to PTP score followed by D-dimer analysis decreases the cost of DVT diagnosis. Conclusions: ICER analysis enables laboratories to choose optimal laboratory tests according to number of patients admitted to laboratory. Results support the feasibility of using PTP scoring and D-dimer measurement before CUS examination in DVT screening.
Introduction
Deep vein thrombosis (DVT) occurs in the western world with a frequency of approximately 1 per 1000 individuals per year (1) . The clinical conditions that predispose DVT are: increasing age, cancer, prolonged immobilization, stroke, previous DVT, congestive heart failure, hormonal treatment, pregnancy or puerperium, acute infl ammatory bowel disease, atherosclerotic disease, long air travel (2, 3) . However, DVT also occurs without an obvious precipitating factor. As DVT is a condition with signifi cant morbidity, rapid diagnosis and effective anticoagulant treatment is required (4, 5) .
The test of choice for clinically suspected DVT is compression ultrasonography (CUS) (6) . The sensitivity for proximal DVT has been reported as 97% but for calf DVT it could be considerably less (73%) (7) . Repeated or serial venous ultrasound examination is indicated for initially negative examination result in symptomatic patients, DVT 'unlikely' patients (by Wells score), and patient with negative D-dimer test (8) . CUS procedure is time consuming and expensive. Therefore, considerable eff orts are being made to design diagnostic algorithms to improve the diagnosis of DVT-suspected outpatients.
Bogavac-Stanojević N. et al. Economic evaluation in the screening of DVT
In recent years, new diagnostic methods involving assessment of clinical probability and D-dimer become proven diagnostic strategy of outpatients with suspect DVT (8) . The inclusion of D-Dimer measurements as a fi rst step in diagnostic work-up was recommended (9) . Recently, a large number of rapid D-dimer assays have been developed for exclusion of DVT. They diff er with respect to assay design, the monoclonal antibodies employed to capture the antigen from plasma, the type of calibrators used and the cut-off levels to exclude DVT. In addition, published reports suggest that the positive and negative predictive values of the various commercial D-dimer assays are highly variable (10) .
Taking into account the clinical symptoms and signs of DVT, calculation of the pre-test clinical probability score (PTP) for DVT before D-dimer measurement and CUS utilisation could be useful (8) . PTP for DVT can be calculated using modifi ed Wells score with nine items: active cancer, paralysis or recent immobilization of the lower limbs, recently bedridden or recent major surgery, localized tenderness, leg swelling, calf swelling, edema of symptomatic leg, collateral veins, previous VTE and alternative diagnosis (8) .
At best, D-dimer alone or in combination with PTP score may be used to confi dently exclude DVT quickly, removing the necessity for time consuming and expensive imaging techniques.
The aims of this study were two-fold: fi rstly to examine the cost-eff ectiveness of the three diff erent D-dimer measurements in the screening of DVT, alone or in combination with PTP, before CUS examination and secondly to compare the total costs of D-dimer assays and CUS utilisation (alone and in combination with PTP) in the screening of DVT and to identify the diagnostic alternative with minimal cost for detecting DVT.
Materials and methods

Subjects
We analyzed data of 192 (95 male and 97 female) prospectively identifi ed outpatients with clinically suspected acute DVT admitted to the vascular ambulance at Department of Clinic for Vascular Surgery, Clinical Centre of Serbia, from January to May 2011. Patients were referred from primary care physicians or sent in from other clinics. Patients were excluded if clinical symptoms persisted for more than 7 days, if they had been hospitalised for more than 3 days at the time of inclusion into the study or had been treated with therapeutic doses of un-fractionated or low-molecular-weight heparin for more than a day or with vitamin K antagonists before attempted inclusion. Patients were not excluded if DVT had occurred previously in the other leg. All included patients were over 18 years of age.
All patients were evaluated by the vascular ultrasound specialist. The data about gender, age and data for calculation of the PTP score were collected. We used scoring system for patient classifi cation. One point was awarded for each of the following items if present: active cancer, paralysis or recent immobilization of the lower limbs, recently bedridden or recent major surgery, localized tenderness, leg swelling, calf swelling, edema of symptomatic leg, collateral veins, previous VTE. Two points were awarded for alternative diagnosis (8) . Patients with a PTP score of less than two (low + moderate PTP) were considered DVT-unlikely, while those with a score of two or more (high PTP) were considered DVT-likely (11).
DVT diagnosis was determined by venous duplex sonography including CUS and colour Doppler visualisation of the veins within the symptomatic leg. Duplex ultrasound examinations were performed by vascular ultrasound specialist according to a standardised protocol and report form (12) CUS was performed within 3 hours of outpatients admission to the vascular ambulance. Patients were classifi ed as DVT positive if they had DVT confi rmed by CUS or as DVT negative if CUS was negative.
All patients gave informed consent prior to their enrolment in the study according to the ethic guidelines following the Helsinki Declaration. The institutional review committee approved our study protocol confi rming that we had followed local biomedical research regulations. 
Statistical analysis
For both decision-analytic models (DAMs) we set the cut-off value at which the negative predictive value (NPV) for D-dimer was at least 95%. For the fi rst DAM we calculated the cut-off value for Ddimer in the total patients group and for the second DAM we calculated the PTP-specifi c cut-off value in the DVT-unlikely group (13 
Outcome, ICER, CMA and sensitivity analysis
The perspective of the incremental cost-eff ectiveness ratio (ICER) analysis is the clinical laboratory setting. To estimate eff ectiveness we calculated the number needed to screen (NNS) to fi nd one true positive patient selected for CUS. The NNS is analogous to "number needed to treat" and it was calculated as the reciprocal value of the diff erence between the prevalence of true positive patients (TPP) and prevalence of false negative patients (FNP). The corresponding formula is:
The meaning of NNS could be interpreted as the number of patients that should be sent to CUS to fi nd one DVT positive patient. In other words, the smaller the NNS the more accurate is the D-dimer test for DVT diagnosis. NNS depends on cut-off values for a particular D-dimer assay.
For ICER analysis we also calculated the NNS% (100/NNS), a value with a clearer clinical understanding. The meaning of NNS% could be interpreted as the percentage of patients that should be sent to CUS to fi nd one from 100 DVT positive patients.
For each DAM we performed ICER analysis by ranking the three alternatives by their increasing costs. After eliminating alternatives that were more or equally costly and less eff ective than a competing alternative (ie; ruled out by simple dominance), the ICER of each alternative was calculated as the additional cost of that alternative divided by its additional eff ectiveness, compared with the next most costly alternative (17) .
Another point of interest was the cost from the perspective of a third-party payer -Republic Institute for Health Insurance (RIHI), the leading health care provider, responsible for health care of almost the entire Serbian population (7.5 million). Outcome of interest was DVT diagnosis. If outcomes are known to be equal, only costs are analysed and the least costly alternative is chosen (17) . We calculated all direct costs required to diagnose DVT per patient:
direct cost = direct cost per D-dimer tests + (number of patients selected for CUS × direct cost per CUS examination).
In this cost minimisation analysis (CMA), we compared direct costs for all six strategies (three strategies from the fi rst DAM and three strategies from the second DAM).
However, we applied the sensitivity analyses. Sensitivity analyses were conducted for factors that could possibly restrict the generalisability of the study results. This approach systematically varies the critical parameters of variables to determine whether the overall decision criteria changes (18) . In our analysis critical variables are costs and eff ectiveness; we varied them within specifi c intervals and recalculated results in order to see the magnitude of change on the fi nal estimate. Two-way sensitivity analysis was performed by simultaneously varying the total costs and eff ectiveness within the given intervals (19) . NNS were varied within the 95% CI and cost according to the number of daily outpatients to the vascular ambulance. To the vascular ambulance the average number of daily outpatients is 3. The base costs used were the average costs per patient using the service when 3 patients are admitted to vascular ambulance per day. However, for sensitivity analyses we used costs for minimal number of outpatients at the vascular ambulance (1 patient) and for 10 patients. We assumed that range of 1 to 10 patients for cost calculation included all necessary variation in costs for controls and calibrations.
Results
Costs calculation
The direct cost estimations were based on the costs of diagnostic procedures and staff doctor visits. The consumed diagnostic procedures included measurements of D-dimer concentration by D-dimer assays, consumables required for operation of the automated analyser and disposables needed for specimen collection and sample analysis. Furthermore, diagnostic procedures included CUS utilisation.
We calculated costs per patient that used the laboratory service. These costs included cost for Ddimer test reagents, for controls (low and high), calibrators and standards, all calculated per patient. The assumption for this calculation is that average number of daily admitted patients to the vascular ambulance is three (Table 1) . We calculated the costs for laboratory specialists and laboratory technicians. The costs of laboratory specialists were the same for all D-dimer analyses, since evaluation of results takes approximately same amount of time. To this we added the costs for the laboratory technician's time for specimen collection, specimen centrifugation and D-dimer measurements. Laboratory technician's costs were diff erent since every D-dimer assays required diff erent time for measurement. In addition, we added the cost of a doctor visit. The costs of a doctor visit were the same since examination of patients takes approximately the same amount of time for all screening alternatives. For ICER analysis we summarised cost for D-dimer reagents, costs for the laboratory technician's time, cost of laboratory specialist and the cost of a doctor visit. The total cost for CMA was calculated by adding the costs for CUS procedure to previously mentioned costs. The cost for vascular ultrasound specialist is included in the cost for CUS procedure.
Due to the fact that we set the cut-off values at which the NPV was at least 95% in every diagnostic alternative FNP were 2. If patients have a low Ddimer value, the D-dimer level should be re-analysed after seven days (8) . Accordingly, all costs for patients with low D-dimer value were doubled.
Administrative costs (e.g. electricity) were excluded from the calculations since these costs are the same for all compared strategies. Non-health care costs and indirect costs were not included in the analysis. All costs are calculated in Euros.
In order to estimate the average cost per patient we used market prices and prices of RIHI for 2011 (20) . The former refers to the average prices for laboratory tests. The latter refers to the estimated actual average prices of staff doctor visits, laboratory technicians, laboratory specialist work, disposables needed for specimen collection and CUS utilisation ( Table 1 ).
The decision-analytic models
The fi rst DAM involved all the included outpatients (the total patient group) and the selection procedure according to D-dimer measurements. Within it we estimated the number of patients selected for CUS and costs of three strategies: DVT screening with Innovance D-dimer reagents; DVT screening with D-dimer Hemosil HS reagents and DVT screening with Vidas D-dimer Exclusion II ( Figure  1 , Panel a). In the second DAM selection of patients was the fi rstly done according to PTP score. 34 outpatients had high PTP. As the prevalence of DVT patients with high PTP is 75-80% (1,5), CUS was performed without D-dimer testing only for these 34 patients (Figure 1, Panel b) . The remaining 158 patients with low and moderate PTP (DVT-unlikely group) were selected for CUS according to D-dimer measurements and costs were calculated for three strategies as in the previous model.
Base case analysis
The NNS value (1.87) was higher in the fi rst DAM than NNS value (1.66) in the second DAM when the selection was made according to the Innovance Ddimer assay. In contrast, NNS values selected according to Hemosil D-dimer HS assay and Vidas Ddimer Exclusion II assays were higher in the fi rst DAM (Figure 1 , Panel a and Panel b).
Diagnostic strategies employing diff erent D-dimer assays were compared using ICER analysis. The results for both DAM are shown in CMA results are presented in Table 3 . The total average cost per patient for each diagnostic alternative, according to the number of patients selected for D-dimer testing and CUS utilisation, in DAMs with or without PTP scoring is indicated. It is clear that the selection of patients according to PTP score followed by D-dimer analysis decreases the number of patients selected for CUS examination as well as the average cost per patient for all three D-dimer assays. The diagnostic alternative employing PTP scoring followed by Hemosil D-dimer HS measurement was less costly in comparison to other strategies. Savings were up to 14.26 Euros per patient.
Sensitivity analysis
To examine the robustness of the results we performed sensitivity analysis by varying the average cost per patient using the service when 1 patient and 10 patients are admitted at the vascular ambulance per day (Table 1) . According to the sensitivity analyses, results were sensitive to the change in the cost of the Hemosil D-dimer HS assay. The Vidas D-dimer Exclusion II assay gave the lowest ICER, but the Hemosil D-dimer HS assay was the most cost-eff ective alternative at cost values below 36 Euros in the fi rst DAM and below 21 Euros in the second DAM, Figure 2a and 2b. This means that the Hemosil D-dimer HS assay was the most cost-eff ective alternative if the cost of the assay was dropped below 21.5 Euros (base case analysis 27.72 Euros) for both DAMs. Furthermore, if only one patient was admitted to the vascular ambulance per day for the fi rst DAM, Hemosil D-dimer HS assay was the most cost-eff ective alternative.
Discussion
The purpose of this study was to assess the three diff erent D-dimer measurements followed by CUS examination against the same three D-Dimer measurement and CUS examination in combination with PTP assessment. A CMA was applied since the data of the alternatives under investigation indicated an equal number of patients with DVT diagnosis but revealed signifi cant variation in the number of patients selected for CUS and D-dimer testing and accordingly diff erent economic burden. In addition, ICER analysis was applied since all three D-dimer measurements had diff erent eff ectiveness. The scope of the analysis was focused on the fi nancial consequences for the third-party payer -RIHI (CMA) and the clinical laboratory in hospitals (ICER analysis).
From all the diagnostic strategies in both DAMs the Vidas D-dimer Exclusion II measurement was the most cost eff ective alternative when more than one patient were admitted at the vascular ambulance per day. However, the Hemosil D-dimer a decision tree and cost model to estimate the United States (US) health care costs for total DVT, total hospital-acquired DVT, and total "preventable" DVT. Annual total DVT cost ranges in 2010 were $7.5 to $39.5 billion (5,6 to 29.9 billion Euros). When the sensitivity analysis was applied (taking into consideration higher incidence rates and costs) annual US total DVT costs ranged from $9.8 to $52 billion (from 7.42 to 39.36 billion Euros) (29) .
Conclusion
Our results support the feasibility of using PTP scoring and D-dimer measurement as the fi rst step in DVT screening from a clinical laboratory and a third party payer perspective. In times of tight economic resources, the introduction of PTP scoring before D-dimer measurement and CUS utilisation would be highly convenient because it is simple to perform. Similarly, implementation of the faster Ddimer test is feasible not only for a clinical laboratory but also from a third-party payer perspective. Our study illustrated that the use of ICER enables laboratories to choose optimal laboratory tests according to number of patients admitted to laboratory and it could be a part of integrative approach to DVT diagnostics. In addition, analytical evaluation could help to understand where and how cost can be restrained.
